Magnetic resonance imaging – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Magnetic resonance imaging – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Gadoquatrane with Gadoteric Acid, Gadobutrol, and Gadoteridol for MRI in Adults with Brain or Spinal Cord Issues https://clinicaltrials.eu/trial/study-comparing-gadoquatrane-with-gadoteric-acid-gadobutrol-and-gadoteridol-for-mri-in-adults-with-brain-or-spinal-cord-issues/ Wed, 29 Apr 2026 14:26:56 +0000 https://clinicaltrials.eu/trial/study-comparing-gadoquatrane-with-gadoteric-acid-gadobutrol-and-gadoteridol-for-mri-in-adults-with-brain-or-spinal-cord-issues/ This clinical trial is focused on evaluating the effectiveness and safety of a new contrast agent called gadoquatrane for use in MRI scans. The study is specifically looking at adults who have known or suspected issues with their brain or spinal cord, which are part of the central nervous system. The trial will compare gadoquatrane to other approved contrast agents that are already used in medical practice, such as gadoteric acid, gadobutrol, and gadoteridol. These agents help improve the clarity of MRI images, making it easier for doctors to see and diagnose problems.

The purpose of the study is to determine if gadoquatrane is as effective as the existing contrast agents. Participants in the study will undergo two MRI scans: one using gadoquatrane and another using one of the other approved contrast agents. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which contrast agent is being used during each scan. This helps ensure that the results are unbiased and reliable.

Throughout the study, researchers will assess various aspects of the MRI images, such as how well the contrast agent highlights different areas and how clearly it defines the structures within the brain or spinal cord. The study will also monitor any side effects or adverse reactions to the contrast agents. The goal is to provide valuable information about the potential benefits and risks of using gadoquatrane in MRI scans for diagnosing central nervous system conditions.

]]> Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans https://clinicaltrials.eu/trial/study-on-how-gadoquatrane-works-and-its-safety-in-children-undergoing-mri-scans/ Wed, 29 Apr 2026 14:26:40 +0000 https://clinicaltrials.eu/trial/study-on-how-gadoquatrane-works-and-its-safety-in-children-undergoing-mri-scans/ This clinical trial is focused on studying how the substance gadoquatrane behaves in the body and its safety in children who need a special type of scan called a contrast-enhanced magnetic resonance imaging (MRI). The study involves children from birth up to 18 years old who require this scan for various medical reasons. Gadoquatrane is given as a solution for injection, and it helps to improve the quality of the MRI images by enhancing the contrast.

The purpose of the study is to understand how gadoquatrane moves into, through, and out of the body after a single injection. The study will observe how the body processes this substance and will monitor any side effects that may occur. The children participating in the study will receive a single dose of gadoquatrane through an intravenous injection, which means it is injected directly into a vein.

Throughout the study, researchers will collect information on how gadoquatrane is distributed in the body and how quickly it is cleared. They will also keep track of any side effects that might happen within a week after the injection. This information will help determine the safety and effectiveness of gadoquatrane in improving MRI scans for children.

]]> Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions https://clinicaltrials.eu/trial/study-comparing-gadoquatrane-with-gadoteric-acid-gadoteridol-and-gadobutrol-for-mri-in-patients-with-non-cns-conditions/ Wed, 29 Apr 2026 14:23:27 +0000 https://clinicaltrials.eu/trial/study-comparing-gadoquatrane-with-gadoteric-acid-gadoteridol-and-gadobutrol-for-mri-in-patients-with-non-cns-conditions/ This clinical trial is focused on evaluating the effects and safety of a new contrast agent called gadoquatrane for use in MRI (Magnetic Resonance Imaging) tests. The study is designed for adults who have known or suspected health issues in any part of the body, except for the brain or spinal cord. The purpose of the study is to compare gadoquatrane with other already approved contrast agents, specifically gadoteric acid, gadoteridol, and gadobutrol, which are commonly used in MRI procedures.

Participants in the study will undergo two MRI scans. One scan will use the new contrast agent, gadoquatrane, and the other will use one of the approved contrast agents. The contrast agents are substances that help improve the clarity of the images produced by the MRI, making it easier for doctors to see and assess any abnormalities. The study aims to determine if gadoquatrane is as effective and safe as the other contrast agents currently in use.

The study will involve a series of MRI scans to assess the effectiveness of the contrast agents in enhancing the images. The results will help determine if gadoquatrane can be a reliable alternative to the existing contrast agents. Participants will be monitored for any side effects or adverse reactions during the study period, which will last for a short duration. The findings from this study could potentially lead to improved imaging options for patients undergoing MRI scans for various health conditions.

]]>